INS and type 2 diabetes mellitus: A meta-analysis of 4 RCT (with a mean follow-up of 16 to 52 weeks) showed that in addition to basal insulin, the amylin analog, pramlintide (120 to 150 μg bid/tid sc) significantly reduced HbA1c (MD =  − 0.33%) in patients with T2DM (compared with placebo or other antidiabetic medications) [101].